๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hangzhou
Clinical trial register · China

Clinical Trials in Hangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine373 Zhejiang University104 First Affiliated Hospital of Zhejiang University103 AstraZeneca76 Zhejiang Cancer Hospital63
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Hangzhou

1812 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment
NCT05926700Soft Tissue Sarcoma
DrugCandonilimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
27
Hangzhou
2024-02-28
Recruiting
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT06161025Solid Cancer
DrugsR-DXd·PLD·Topotecan·Paclitaxel
Daiichi Sankyo
Phase 2/3
860
Beijing, Chongqing, Fuzhou, Guangzhou, Hangzhou, Jinan, Nanning, Shanghai
2024-02-27
Recruiting
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.
Phase 1/2
68
Hefei, Hangzhou, Wenzhou, Beijing
2024-02-23
Active, closed
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
NCT06271837Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
DrugsTrastuzumab deruxtecan·Bevacizumab
AstraZeneca
Phase 2
127
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongyang, Guangzhou, Hangzhou
2024-02-22
Active, closed
Prospective Cohort Study of Panvascular Disease
NCT06295861ASCVD
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
50,000
Hangzhou
2024-02-21
Recruiting
Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment
NCT07122024Helicobacter Pylori
DrugRabeprazole
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
414
Hangzhou
2024-02-19
Active, closed
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140Carcinoma, Non-Small-Cell Lung
DrugsClobetasol·Chlorhexidine·Doxycycline·Minocycline
Janssen Research & Development, LLC
Phase 2
305
Changzhou, Chengdoucun, Chengdu, Guangzhou, Hangzhou, Harbin, Huizhou, Nanjing
2024-02-16
Active, closed
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853Systemic Lupus Erythematosus, CAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine
Phase 1
22
Hangzhou
2024-02-10
Active, closed
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
NCT06151574Lung Cancer, Non-squamous, Non-small Cell
DrugsZongertinib·Pemetrexed·Cisplatin·Carboplatin
Boehringer Ingelheim
Phase 3
428
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Taizhou
2024-02-09
Recruiting
Efficacy of Electroacupuncture Combined With Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol
NCT06261801Trigeminal Herpetic Neuralgia
The Third People's Hospital of Hangzhou
Not applicable
102
Hangzhou
2024-02-07
Recruiting
Early-stage Detection of Liver Cancer by Proteins in Peripheral Blood
NCT06544083Hepatocellular Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
600
Hangzhou
2024-02-05
Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
NCT06478251Tumor, Solid
DrugsNW-301D·NW-301V
TingBo Liang
Phase 1
9
Hangzhou
2024-02-01
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Pembrolizumab·Bevacizumab
Vividion Therapeutics, Inc.
Phase 1
280
Hangzhou, Beijing, Guangzhou
2024-01-25
Recruiting
A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood
NCT06240689Locally Advanced Head and Neck Squamous Cell Carcinoma
DrugSintilimab
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
104
Hangzhou
2024-01-25
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
DrugAflibercept
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies
NCT06224855Advanced Solid Tumors, Hematological Malignancies
DrugDXC006
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
280
Hefei, Guangzhou, Changsha, Nanchang, Hangzhou
2024-01-24
Active, closed
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
NCT06143891Chronic Graft Versus Host Disease
DrugsBelumosudil·Prednisolone·Prednisone
Sanofi
Phase 3
260
Beijing, Changchun, Changsha, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan
2024-01-23
Recruiting
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
NCT06356662Parkinson Disease
DrugTenofovir Disoproxil Fumarate
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1
60
Hangzhou
2024-01-23
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Talquetamab·Teclistamab·Bortezomib
Janssen Research & Development, LLC
Phase 3
838
Beijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hohhot
2024-01-22
Recruiting
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
NCT06214195Cardiotoxicity Induced by Drug Therapy for Breast Cancer
Zhejiang Cancer Hospital
Phase 3
276
Hangzhou
2024-01-20
Active, closed
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
NCT06260163Colitis, Ulcerative
DrugGuselkumab
Janssen Research & Development, LLC
Phase 3
112
Beijing, Changzhou, Hangzhou, Shanghai, Shenyang, Zhengzhou
2024-01-19
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
NCT06210776HER2-positive Breast Cancer, HER2-low Breast Cancer, Breast Cancer, Advanced Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Observational
800
Beijing, Chengdu, Dalian, Foshan, Fuzhou, Guangzhou, Haikou, Hangzhou
2024-01-15
Recruiting
PRevention of OsTEoporotiC FracTure 2 Pilot Study
NCT06134908Fragility Fracture
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
50
Changsha, Dongguan, Guangzhou, Hangzhou, Hefei, Shenzhen
2024-01-13
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-01-11
Recruiting
Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)
NCT06220617Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma
Zhejiang University
Observational
3,600
Hangzhou, Guangzhou, Kunming, Nanjing, Xi'an, Zhengzhou
2024-01-11
Recruiting
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
NCT06214143Advanced Solid Tumors
DrugT3011
Shanghai Pharmaceuticals Holding Co., Ltd
Phase 1/2
68
Anyang, Bengbu, Changsha, Chengdu, Dongwan, Fuzhou, Guangzhou, Hangzhou
2024-01-11
Recruiting
The Study on the Accuracy of Peri-implant Probing and Related Influencing Factors
NCT07004517Peri-Implantitis, Diagnosis
The Dental Hospital of Zhejiang University School of Medicine
Observational
83
Hangzhou
2024-01-11
Recruiting
Rectosigmoid Lesion Excision vs. Resection: A Non-Inferiority Randomized Comparison in Advanced Ovarian Cancer
NCT07616310Ovarian Cancer (OvCa)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
300
Hangzhou
2024-01-10
Recruiting
Steroid Diabetes in Patients With Kidney Disease
NCT06161701Nephrotic Syndrome
Zhejiang Provincial People's Hospital
Observational
300
Hangzhou
2024-01-10
Recruiting
Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab
NCT07253896Safety
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Hangzhou
2024-01-03
Recruiting
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT07256301PNH - Paroxysmal Nocturnal Hemoglobinuria
DrugEA5
Shanghai Lanyi Therapeutics Co., Ltd.
Phase 1
24
Tianjin, Hangzhou
2024-01-03
Active, closed
Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML
NCT07437170Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
DrugSelinexor
The Children's Hospital of Zhejiang University School of Medicine
Phase 2
10
Hangzhou
2024-01-01
Recruiting
Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
NCT06249750Metastatic Castration-resistant Prostate Cancer (CRPC)
Pengyuan Liu
Phase 2
60
Hangzhou
2024-01-01
Recruiting
Multifunctional Cataract Surgery Assistive Instruments Used in Cataract Surgery
NCT06182605Cataract
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
1,000
Hangzhou
2024-01-01
Recruiting
Central Motor Mechanisms in AIS Via HD-sEMG, EEG and Neuromuscular Coupling Analysis
NCT06758115Adolescent Idiopathic Scoliosis
The First Affiliated Hospital of Zhejiang Chinese Medical University
Observational
40
Hangzhou
2024-01-01
Active, closed
LKB1 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer: A Retrospective Cohort Study
NCT07710599Non-small Cell Lung Cancer
Ling Zhiqiang
Observational
300
Hangzhou
2024-01-01
Recruiting
A Biomechanical Study of the Lumbar Intervertebral Disc by Lever Positioning Manipulation
NCT06872918Lumbar Disc Herniation
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
128
Hangzhou
2024-01-01
Recruiting
Acupoint Selection Based on Meridian Theory in Primary Insomnia of Liver Depression and Spleen Deficiency Type
NCT06782815Primary Insomnia
Chuanlong Zhou
Not applicable
96
Hangzhou
2024-01-01
Recruiting
Multi Center Observation of Sentinel Skin Graft for Detecting Acute Rejection After Renal Transplantation
NCT05600634Kidney Transplant Rejection, Skin Graft
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
24
Xi'an, Hangzhou
2024-01-01
Recruiting
The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma
NCT06266832Rectal Adenocarcinoma
DrugsAdebrelimab·Oxaliplatin·Capecitabine
Sir Run Run Shaw Hospital
Phase 2
30
Hangzhou
2024-01-01
Recruiting
Ribociclib in Combination With Adjuvant Endocrine Therapy for Patients With Early High-risk HR+HER2- Breast Cancer
NCT06587789Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
286
Hangzhou
2024-01-01
Recruiting
Dementia Risk Registry Across the Multidimensional Lifespan: A 10-Year Study
NCT06164262Cerebral Small Vessel Diseases, Dementia, Mixed, Health Behavior, Health Behavior, Risky
Zhejiang Provincial People's Hospital
Observational
1,000
Hangzhou
2024-01-01
Not yet open
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
NCT06195670CRC, Metastatic Colorectal Cancer, Metastatic Colorectal Adenocarcinoma
Zhejiang Cancer Hospital
Phase 1/2
220
Hangzhou
2024-01
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945Breast Cancer
DrugTrastuzumab deruxtecan
Daiichi Sankyo
Phase 3
250
Beijing, Fujian, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanchang
2023-12-30
Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
NCT06090539Relapsed/Refractory Non-Hodgkin Lymphoma
DrugsGolcadomide·Mosunetuzumab·Epcoritamab·Rituximab
Bristol-Myers Squibb
Phase 1/2
460
Beijing, Guangzhou, Zhengzhou, Suzhou, Nanchang, Shenyang, Shanghai, Hangzhou
2023-12-29
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
2023-12-29
Recruiting
a PROspective Case Control Study to Develop and Validate a Blood Test FOr mUlti-caNcers Early Detection๏ผˆPROFOUND๏ผ‰
NCT06217900Cancer
Shanghai Weihe Medical Laboratory Co., Ltd.
Observational
16,666
Beijing, Changchun, Guangzhou, Hangzhou, Shenyang
2023-12-28
Recruiting
The Efficacy and Safety of the COMBO Endoscopy Oropharyngeal Airway in Gastrointestinal Endoscopy Procedure
NCT06081647Hypoxia, Gastric Polyp, Colon Cancer, Esophageal Cancer
RenJi Hospital
Not applicable
1,200
Nanjing, Nanchang, Jinan, Shanghai, Xiโ€™an, Tianjin, Hangzhou
2023-12-27
Recruiting
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
NCT06235229Multiple Myeloma
DrugGC012F
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2
110
Beijing, Hangzhou, Jinan, Shanghai, Shenyang, Wenzhou, Wuhan, Xi'an
2023-12-26
Recruiting
Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)
NCT05872685Adenocarcinoma of the Stomach, Adenocarcinoma of Esophagogastric Junction, Proficient Mismatch Repair
DrugsS1·Serplulimab·Oxaliplatin
Yu jiren
Phase 2
314
Hangzhou, Lishui, Ningbo, Taizhou
2023-12-24
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Guangzhou, Xi'an, Jinan, Hangzhou, Wenzhou, Beijing, Shanghai, Shenzhen
2023-12-12
Recruiting
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
NCT06253130Advanced Solid Tumor
Eikon Therapeutics
Phase 1/2
156
Guangzhou, Shijiazhuang, Jinan, Hangzhou, Chongqing, Fuzhou, Shanghai
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2023-12-11
Recruiting
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
NCT05947344AML, Adult
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1
84
Hangzhou
2023-12-08
Recruiting
Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
NCT06155305Organoids, Breast Cancer, Neoadjuvant Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
58
Hangzhou
2023-12-06
Recruiting
Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder
NCT06109337ADHD, Immune System, Clinical Syndrome
First Affiliated Hospital of Zhejiang University
Observational
100
Hangzhou
2023-12-04
Recruiting
Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not
NCT06463717Multiple Myeloma, Minimal Residual Disease
First Affiliated Hospital of Zhejiang University
Observational
210
Hangzhou
2023-12-01
Recruiting
Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women
NCT06417736Endometrial Cancer Stage I, Endometrial Hyperplasia
DrugMegestrol Acetate
Women's Hospital School Of Medicine Zhejiang University
Not applicable
75
Hangzhou
2023-12-01
Recruiting
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients
NCT06023212Metastasis Spinal Tumor
DrugTranexamic Acid
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
150
Hangzhou
2023-12-01
Active, closed
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
NCT06194825Transthyretin Amyloid Cardiomyopathy
AstraZeneca
Phase 3
64
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Haโ€™erbin, Jinan
2023-12-01
Active, closed
Rapid Abdominal Diagnosis With AI & Radiology
NCT07040358Abdominal Diseases
First Affiliated Hospital of Zhejiang University
Observational
2,000,000
Hangzhou
2023-12-01
Not yet open
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
NCT06140576Breast Neoplasms
Zhejiang Cancer Hospital
Phase 1/2
58
Hangzhou
2023-11-30
Recruiting
Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome
NCT06125405Nephrotic Syndrome in Children, Telitacicept
DrugTelitacicept
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
20
Hangzhou
2023-11-28
Recruiting
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
NCT05737303Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
Women's Hospital School Of Medicine Zhejiang University
Phase 3
538
Guangzhou, Ji'nan, Hangzhou, Ningbo, Wenzhou
2023-11-27
Recruiting
Clinical Evaluation of Surrounding Electroacupuncture in the Treatment of Acute Lateral Ankle Sprain
NCT06182943Electroacupuncture
The Third Affiliated hospital of Zhejiang Chinese Medical University
Not applicable
84
Hangzhou
2023-11-23
Recruiting
18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.
NCT06164561Myelofibrosis
First Affiliated Hospital of Zhejiang University
Observational
57
Hangzhou
2023-11-21
Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT06120166Diffuse Large B-cell Lymphoma
He Huang
Phase EARLY_PHASE1
18
Hangzhou
2023-11-16
Recruiting
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis ๏ผˆEGPA๏ผ‰
NCT05979051Eosinophilic Granulomatosis With Polyangiitis
DrugsSHR-1703·Mepolizumab
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDato-DXd·Epirubicin·Olaparib·Doxorubicin
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Recruiting
LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
NCT07252362The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
Zhejiang Cancer Hospital
Not applicable
20
Hangzhou
2023-11-11
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Nivolumab·Pemetrexed
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
DrugBMS-986435
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
DrugsRelmacabtagene Autoleucel·Fludarabine·Cyclophosphamide
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
NCT06082050Transthyroxin Amyloidosis Cardiomyopathy
Zhejiang University
Phase EARLY_PHASE1
7
Hangzhou
2023-11-02
Recruiting
Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
NCT06139042Liver Cancer, Biliary Tract Cancer, Pancreatic Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
1,608
Hangzhou
2023-11-01
Recruiting
Oriental Intervention for Enhanced Neurocognitive Health (Orient) Diet in Populations With High Risk of Stroke (ENDS)
NCT06098235High Risk of Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
160
Hangzhou
2023-11-01
By invitation
Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
NCT06044324Treatment Resistant Depression, Visual Perceptual Weakness
First Affiliated Hospital of Zhejiang University
Not applicable
42
Hangzhou
2023-11-01
Recruiting
Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized๏ผŒOpen-label Clinical Trial.
NCT06079788Nephrotic Syndrome in Children
Mao Jianhua
Phase 3
140
Wuhan, Nanjing, Kunming, Hangzhou, Ningbo, Wenzhou, Beijing, Shanghai
2023-11-01
Recruiting
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
NCT07504523Metastatic Colorectal Cancer (CRC)
Ying Yuan, MD
Phase 1
20
Hangzhou
2023-11-01
Recruiting
Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN
NCT05842109ABO Hemolytic Disease of Newborn
Women's Hospital School Of Medicine Zhejiang University
Observational
112
Hangzhou
2023-10-31
Recruiting
Preventive Effect of Probiotics in GDM
NCT06938464Gestational Diabetes Mellitus (GDM)
Women's Hospital School Of Medicine Zhejiang University
Not applicable
334
Hangzhou
2023-10-27
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
NCT06182696Relapsed and/or Refractory Multiple Myeloma
DrugOriCAR-017
OriCell Therapeutics Co., Ltd.
Phase 1/2
83
Hangzhou, Beijing, Nanjing, Shanghai, Wuhan
2023-10-26
Recruiting
Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer
NCT06019923Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Observational
100
Hangzhou
2023-10-26
Recruiting
Routine Angiography Follow-Up After Percutaneous Coronary Intervention in High-Risk Patients
NCT05923489Coronary Artery Disease
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
2,618
Hangzhou
2023-10-26
By invitation
T-DM1 Combined With CDK4/6 Inhibitor Ribociclib
NCT06481956HER2-positive Advanced Breast Cancer
Zheng Yabing
Phase 2
40
Hangzhou
2023-10-25
Recruiting
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
NCT06190639Esophageal Squamous Cell Carcinoma
DrugSintilimab
Zhejiang Cancer Hospital
Phase 2
31
Hangzhou
2023-10-25
Active, closed
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277Metastatic Non-small Cell Lung Cancer
DrugsVolrustomig·Pemetrexed·Carboplatin·Pembrolizumab
AstraZeneca
Phase 3
895
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2023-10-24
Recruiting
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
NCT06084962Relapse/Refractory Multiple Myeloma
He Huang
Phase 1
40
Hangzhou
2023-10-20
Recruiting
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
NCT06046313Acute Myeloid Leukemia, Myelodysplastic Syndromes
DrugDecitabine
First Affiliated Hospital of Zhejiang University
Phase 2
120
Hangzhou
2023-10-19
Active, closed
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes
NCT06091267Myelodysplastic Syndromes
DrugsDecitabine and Cedazuridine·Decitabine
Otsuka Beijing Research Institute
Phase 1/2
72
Hangzhou
2023-10-16
Not yet open
Observational Study for SIR-Spheres Therapy for the Treatment of Unresectable Metastatic Liver Tumors From Primary Colorectal Cancer
NCT06079242Colorectal Neoplasms
GrandPharma (China) Co., Ltd.
Observational
200
Hangzhou
2023-10-15
Recruiting
DAREONโ„ข-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT05882058Small Cell Lung Carcinoma, Neuroendocrine Neoplasms, Extra-pulmonary Neuroendocrine Carcinoma
Boehringer Ingelheim
Phase 2
204
Chengdu, Hangzhou, Jinan, Nanchang, Shanghai
2023-10-13
Recruiting
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
NCT06082037Lung Transplant Rejection
DrugsAzithromycin·Belumosudil
Sanofi
Phase 3
180
Beijing, Chengdu, Fuzhou, Guangzhou, Hangzhou, Hefei, Shanghai, Wuxi
2023-10-10
Recruiting
A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency
NCT06067529Premature Ovarian Insufficiency
Women's Hospital School Of Medicine Zhejiang University
Observational
1,080
Hangzhou
2023-10-10
Recruiting
CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection
NCT06560827HCC
CARsgen Therapeutics Co., Ltd.
Phase 1
30
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guanzhou, Hangzhou, Shanghai
2023-10-08
Recruiting
Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)
NCT06057402Multiple Myeloma
DrugElranatamab
Pfizer
Phase 4
80
Beijing, Guangzhou, Jinan, Hangzhou
2023-10-03
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Chongqing, Suzhou, Xi'an, Shanghai, Hangzhou
2023-10-02
Recruiting
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors
NCT05892718Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma
DrugHCB101
FBD Biologics Limited
Phase 1
80
Hangzhou
2023-10-02
Recruiting
Clinical Study of Single Incision Laparoscopic Cholecystectomy in the Treatment of Patients With Acute Cholecystitis
NCT06074679Cholecystectomy, Laparoscopic
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
600
Huangshan City, Hangzhou, Huzhou, Lishui, Meicheng
2023-10-01
Rows per page Showing 1201–1300 of 1812
Previous 11 12 13 14 15 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/hangzhou?page=13

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,812 of those studies with a site in Hangzhou.

How many clinical trials are recruiting in Hangzhou?

1,096 of the 1,812 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 300 have not yet opened recruitment, 372 are active but closed to new participants, and 44 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.